Panagis Galiatsatos, MD, MHS, provides clinical insights on resources and factors that inform the treatment of patients with bronchiectasis.
Video content above is prompted by the following questions:
Chronic Respiratory Diseases Linked to Other Noncommunicable Diseases in Vulnerable Countries
August 4th 2025Despite their devastating global impact, chronic respiratory diseases remain a hidden threat in low- and middle-income countries, often going undiagnosed in adults who are already battling other noncommunicable diseases.
Read More
Preventing Respiratory Illness and Death Through Tighter Air Quality Standards
June 1st 2021On this episode of Managed Care Cast, a research scholar at the Marron Institute of Urban Management at New York University discusses the latest findings in the Health of the Air report, which was presented at the recent American Thoracic Society 2021 International Conference.
Listen
Depemokimab Reduces Exacerbations Regardless of Baseline Asthma Control
July 3rd 2025Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being reviewed by the FDA.
Read More
Camlipixant May Benefit Patients With High-Burden RCC
June 25th 2025A phase 2a trial of camlipixant, a selective P2X3 receptor antagonist, found that while the drug did not significantly reduce cough frequency in the overall population with refractory chronic cough, it produced meaningful improvements in patients with a higher baseline cough burden.
Read More